A comparative dosimetric study of left sided breast cancer after breast-conserving surgery treated with VMAT and IMRT

Hongfu Zhao1†, Mingyuan He1†, Guanghui Cheng1*, Dongmei Han1, Ning Wu1, Dan Shi1, Zhipeng Zhao1 and Jianxue Jin2

Abstract

Background and purposes: This study compared VMAT and IMRT plans for intact breast radiotherapy for left sided breast cancer and evaluated the irradiated dose of planning target volume and OARs, especially focusing on heart and coronary artery.

Materials and methods: Eleven patients with left sided breast cancer whose breast was relatively smaller (the mean volumes is 296 cc) treated with breast-conserving surgery were prescribed radiotherapy of 50 Gy in 25 fractions using two or four-field step and shoot IMRT (2 or 4-F IMRT), and one or two-arc VMAT (1 or 2-arc VMAT). The 10 Gy electron boost to the tumor bed after delivery of 50 Gy was not included in the analysis. Multiple planning parameters for the PTV and the PRV-OARs were measured and analyzed.

Results: Treatment plans generated using VMAT had better PTV homogeneity than the IMRT plans. For the PRV-OARs, the 1-arc VMAT had significantly higher Dmean and V5 for left lung and heart, and showed worse Dmean for liver, esophagus, spinal cord, contralateral lung and breast. In contrast, the 2-arc VMAT and the 2-F or 4-F IMRT plans showed better results for the PRV-OARs than the 1-arc VMAT. However, for the heart and coronary artery, the 1-arc VMAT showed better V20 and V40 compared with the other plans. Moreover, the 2 F-IMRT had specially advantage on V5 and V20 for heart and V5 for coronary arteries, the 2-F IMRT also showed a greater MU and treatment times. Using the table of quality score to evaluate the plans, we found that 2-F IMRT had the highest scores of 13, followed by the 2-arc VMAT plan (10 points) and 1-arc VMAT plan (8 points), and finally the 4-F IMRT plan (6 points). Moreover, when a dose comparison for heart minus coronary artery was calculated, the V20 and V40 for the rest of heart in all plans were very small and closed, indicating the dose to the coronary artery contributed dramatically to the high dose volumes for the entire heart.

Conclusions: Compared to other plans, the 2-F IMRT plan with fewer monitor units and shorter delivery time is an appropriate technique for left sided breast cancer, which achieved good PTV coverage and sparing of organs at risk besides for the heart and coronary artery.

Keywords: Left sided breast cancer, IMRT, VMAT, Dosimetry
Introduction

Breast cancer is the most common cancer among women. About 1.2 million women are newly diagnosed with breast cancer each year in the world, and 500,000 women die of it each year. Therefore, the breast cancer remains the primary cause of cancer mortality in women after lung cancer. A number of randomized controlled clinical trials have shown that breast-conserving surgery (BCS) combined with post-operative radiation therapy (PORT) [1] has the same curative effect as the Halsted radical mastectomy [2], making this the primary therapeutic strategy for Stages I and II breast cancer. PORT has been shown to substantially reduce the rate of local relapse and improve long-term survival [3] but at the cost of morbidity to the heart [4], lung [5] and a risk of secondary breast cancer [6]. Among these Organs at Risk (OARs), the heart is one of the most important, in particular in relation to radiotherapy for left-sided breast cancer where cardiac dose has been associated with increased cardiac mortality [7, 8].

Three-dimensional conformal radiation therapy (3-D CRT) and intensity-modulated radiation therapy (IMRT) techniques have been implemented across China. Traditionally, breast radiotherapy used a fluoroscopic technique with two dimensional planning. This was followed by 3-D CRT with two conventional tangential radiotherapy fields. IMRT has been widely used for the past decade, permitting variation of fluence across the radiotherapy fields, and allowing optimal dose distribution according to an individual's anatomy. It has been suggested that IMRT results in improved dose homogeneity within the irradiated breast with added sparing of the heart and lung when compared with 3-D CRT [9, 10]. Breast IMRT ranges from photon-only IMRT to mixed electron and photon IMRT with 2 to 16 fields of various photon and electron beam energies [11]. Dogan et al. [12] investigated the number of beams necessary for optimal dose coverage of the breast and found that 4-field IMRT was the best choice. A newer technique known as volumetric modulated arc therapy (VMAT) was introduced in 2007 as a novel extension of IMRT, in which an optimized three-dimensional dose distribution could be delivered in a single gantry rotation. Compared to IMRT planning, VMAT resulted in even better Planning Target Volume (PTV) coverage and sparing of OARs than IMRT [13]. However, Badakhshi et al. argued that VMAT was inferior to IMRT and 3D-CRT with regard to dose distribution to organs at risk, especially at the low dose level, therefore VMAT was not recommended for breast cancer treatment compared with IMRT or conventional radiotherapy [14]. To further assess the advantages and the disadvantages of different IMRT and VMAT plans in whole left breast irradiation for the breast cancer patient, the VMAT (1 and 2-arc VMAT) plans and IMRT (2 and 4-field IMRT) plans were examined in a prospective clinical setting to adequately evaluate the irradiated dose analysis of planning target volume and OARs, especially focusing on heart coronary artery (CA).

Material and methods

Patients
Eleven patients with stage 0 (two patients), stage I (five patients) and stage II (four patients: two patients were diagnosed with N1) left-sided breast cancer were randomly selected for this treatment planning study. They had undergone breast-conserving surgery. The mean patient age at treatment was 45 years (range from 32 to 67 years). This study was approved by the Research Ethics Board of the China-Japan Union Hospital of Jilin University, and all patients agreed to the conditions of this trial. Completed informed consent forms were obtained from each patient.

Target and normal tissue delineation
The breast Clinical Target Volume (CTV) included all visible breast parenchyma, retracted 5 mm from the skin surface. The Planning Target Volume (PTV) comprised the CTV with a 7 mm circumferential margin to allow for daily set-up variations and account for setup uncertainties and respiratory motion, and was also retracted 5 mm from the skin surface. The breast PTVs ranged from 149 cm$^3$ to 537 cc (296.6 ± 122.2 cc).

The Planning Risk Volume (PRV) of all the involved OARs, including contra-lateral breast, entire heart, coronary artery area, liver, spinal cord, esophagus, left lung and right lung were outlined by the treating physician. According to the American Memorial Sloan-Kettering Cancer Research Methods (AMSK CRM), one-fourth of the left anterior aspect of the heart, up to 1 cm subsurface, is identified as the volume encompassing the coronary artery (CA) area [15].

Planning procedure
Both VMAT and step and shoot IMRT plans were completed in the three-dimensional treatment planning system (TPS) Monaco® v.3.20.02 Elekta AB, Stockholm, Sweden). The TPS determines densities in the body based on CT density calibration curves, and calculates dose with a Monte Carlo Photon algorithm, taking into account the calibration for an inhomogeneous medium. An Elekta Synergy® (Elekta AB, Stockholm, Sweden) linear accelerator fitted with the Multi Leaf Collimator MLCi® (1 cm leaf width) was used with a 6 MV photon energy beam. All plans were normalized to the 95 % isodose line encompassing 95 % of the PTV (V95% = 47.5 Gy).

The 2-F IMRT plan used two opposed modulated fields, which suited the PTV curved shape and orientation. The gantry angle was determined according to the angle of the curve formed by the PTV. On the basis of the 2-F IMRT,
the 4-F IMRT plan added two modulated fields, thereby better avoiding the coronary artery area. A 2-arc VMAT (4 shuttle subarcs) plan was generated using two small 40° rotations (the gantry angle of middle line of the arc was identical with the direction with the 2-F IMRT and was same with it) which followed the orientation of the 2-F IMRT. The 1-arc VMAT (2 shuttle subarcs) plan was generated using a single 210° rotation with a starting angle and ending angle similar to that of the 4-F IMRT. This sector angle was used to avoid entrance doses to the contralateral lung and heart. The minimum subarc segment area was 2 cm²; the minimum number of monitor units was four; the maximum number of control points per arc was 60; the minimum segment width was 1 cm, and the fluence smoothing was at medium level. The four-field arrangements are shown in Fig. 1, and use the same optimization objective. Optimization prioritized normal tissue constraints, and used segment shape optimization.

Prescribed dose
The prescription dose to the whole breast was 50 Gy in 25 fractions (D50 = 50 Gy) according to the ICRU report number 83 recommendations [16]. The prescription properties are shown in Table 1 under Monaco system. We used a 10 Gy electron boost to the tumor bed after delivery of 50 Gy to the entire breast (not included in the doses analyzed).

Dosimetric evaluation parameters
The following parameters were evaluated to assess plan quality: for the PTV, the dose to 98 and 2 % of the volume (D98 % and D2 %, respectively) and the part of the PTV receiving more than 107 % of the prescribed dose (V107 %) were explicitly calculated. Additionally, the Homogeneity Index (HI) was calculated according to ICRU 83 [17]: HI = (D2 %–D98 %)/D50 %. The Conformity Index (CI) as proposed by Paddick et al. [18] was evaluated: CI = V47.5/PTV. The Conformity Number (CN) = (VPTV47.5/VPTV)/(VPTV47.5/VBody47.5), and integral dose (ID) = VBody × DMean in body, outside PTV were also reconstructed. Total treatment delivery time was measured on the quality assurance model in phantom and recorded from end of phantom setup to the end of the treatment, not including the idle frame time. The primary field switching system could trigger automatically.

Plans of quality analysis in population and individual case
To better summarize the most superior technique from the multi-parameter results of our study, we use the quality score table of the plans for evaluation. The parameter setting in the table was chosen according to the weight factors of our concerning in our research. In the score table, it is scored to point 1 if one parameter showed significant advance (p < 0.05) comparing with another parameter among the different plans, otherwise scored to 0. And only the best index/indices could get 1 point in each parameter. Moreover, we used individual plan comparison table for evaluating the technique in each parameter/patient by tabulating the number of the patients and recording or calculating the best plan (with favorable index among the four plans).
Statistics
All results were compared and analyzed using a two-sided paired t-test by SPSS 11.5 software, and a statistical significance level of 0.05 was used (p < 0.05).

Results

Dose analysis of planning target volume
Figure 2 shows axial dose distributions with VMAT and IMRT. Both VMAT and IMRT achieved 95% coverage of the PTVs. Mean values for HI, CI and CN are presented in Table 2. We found that both VMAT and IMRT achieved good dose homogeneity across the whole breast for all patients in this study. The two VMAT plans have better HI and CI than the two IMRT plans, and decreased V107, too. However, the difference in HI and CI was not significant between any two IMRT or VMAT plans.

MUs and delivery time
Table 2 also shows that MUs and the estimated treatment time per 2 Gy fraction for the 2-F IMRT plan was significantly lower than other three plans. With respect to the both MUs and the treatment time, the values for 1-arc VMAT plans were the worst.

Dose analysis of OARs
The D_{mean} in healthy tissue (outside of the PTV) increased in the plans, from the 2-F IMRT, to 2-arc VMAT, to the 4-F IMRT, to the 1-arc VMAT (Table 3).

Table 1 The prescription properties of the IMRT and VMAT plans

| Structure       | Cost Function                                      | Constraints                                      |
|-----------------|----------------------------------------------------|--------------------------------------------------|
| PTV             | Target Penalty                                     | Prescription:5000 cGy Minimum Volume:50 % Surface Margin:0.5 cm |
|                 | Quadratic Overdose                                  | Maximum Dose:5150 cGy RMS Dose Excess:50 cGy Shrink Margin:0.00 cm |
|                 | Underdose DVH                                       | Objective Dose:4750 cGy Minimum Volume:95 %     |
| Coronary Artery | Overdose DVH                                        | Objective Dose:500 cGy Maximum Volume:76 % Shrink Margin:0.5 cm |
|                 | Overdose DVH                                        | Objective Dose:1000 cGy Maximum Volume:55 % Shrink Margin:0.2 cm |
|                 | Overdose DVH                                        | Objective Dose:2000 cGy Maximum Volume:46 % Shrink Margin:0.1 cm |
| Left Lung       | Maximum Dose                                       | Maximum Dose:4950 cGy Shrink Margin:0.8 cm      |
|                 | Overdose DVH                                        | Objective Dose:500 cGy Maximum Volume:30 % Shrink Margin:0.0 cm Optimize over all voxels in volume |
|                 | Overdose DVH                                        | Objective Dose:1000 cGy Maximum Volume:20 % Shrink Margin:0.0 cm |
|                 | Overdose DVH                                        | Objective Dose:2000 cGy Maximum Volume:15 % Shrink Margin:0.0 cm |
| Heart           | Overdose DVH                                        | Objective Dose:3000 cGy Maximum Volume:3 % Shrink Margin:1.0 cm |
| Right Breast    | Overdose DVH                                        | Objective Dose:500 cGy Maximum Volume:4 % Shrink Margin:0.3 cm |
| Right Lung      | Overdose DVH                                        | Objective Dose:500 cGy Maximum Volume:6 % Shrink Margin:0.0 cm |
| Liver           | Maximum Dose                                       | Maximum Dose:1500 cGy Shrink Margin:0.8 cm      |
| Esophagus       | Maximum Dose                                       | Maximum Dose:500 cGy Shrink Margin:0.0 cm       |
| Spinal cord     | Maximum Dose                                       | Maximum Dose:800 cGy Shrink Margin:0.5 cm       |
| Body            | Quadratic Overdose                                  | Maximum Dose:5000 cGy RMS Dose Excess:30 cGy Shrink Margin:0.00 cm |
|                 | Quadratic Overdose                                  | Maximum Dose:4500 cGy RMS Dose Excess:40 cGy Shrink Margin:1.00 cm |
|                 | Maximum Dose                                       | Maximum Dose:6050 cGy Shrink Margin:0.00 cm Optimize over all voxels in volume |
|                 | Maximum Dose                                       | Maximum Dose:5600 cGy Shrink Margin:0.50 cm     |

Detailed results are given in Table 3.
Dose analysis of heart and coronary arteries
Comparisons for the relevant dosimetric parameters for heart and coronary artery are given in Table 4. The mean dose to the entire heart was smaller for the IMRT plans compared with VMAT plans, but the mean dose to the coronary artery (CA) was similar in all plans. For the heart and CA, the 2-F IMRT plan reduced the V5 compared with other plans. The 1-arc VMAT plan was worse for V5, but showed good result for V20 and V40 compared with other plans. The 2-arc VMAT plan slightly increased the V20 and V40, but no difference was seen compared with the IMRT plans. For dose comparison of the region of interest: entire heart minus coronary artery, the V20 in all the plans was less than 1 % and not significantly different between any two.

Plans of quality score
From the summary of scoring (Table 5), we found that 2-F IMRT had the highest scores of 14 with 4 points from heart and CA, followed by the 2-arc VMAT plan (10 points) with none from heart and CA, and the 1-arc VMAT plan (8 points) with the 4 points from heart and CA, finally

|                | 2FIMRT       | 4FIMRT       | 2ArcVMAT     | 1ArcVMAT     |
|----------------|--------------|--------------|--------------|--------------|
| D98 (Gy)       | 46.2 ± 0.6 ^  | 46.4 ± 0.4   | 46.6 ± 0.4 ^  | 46.6 ± 0.6 ^  |
| D50 (Gy)       | 50.7 ± 0.5 ^  | 50.2 ± 0.3 ^ a | 49.7 ± 0.5 ^ b | 49.7 ± 0.6 ^ b |
| D2 (Gy)        | 53.8 ± 0.7 ^  | 53.5 ± 0.5 ^  | 52.5 ± 0.6 ^  | 52.5 ± 1.1    |
| V107           | 4.6 % ± 5.4 % | 2.2 % ± 1.8 % | 0.6 % ± 1.1 % | 0.7 % ± 0.9 % |
| HI             | 0.150 ± 0.022 | 0.140 ± 0.016 | 0.118 ± 0.018 | 0.120 ± 0.029 |
| CI             | 1.34 ± 0.10 ^  | 1.32 ± 0.10 ^  | 1.24 ± 0.07 ^ a | 1.16 ± 0.05 ^ b |
| CN             | 0.677 ± 0.050 | 0.685 ± 0.051 | 0.728 ± 0.036 ^ a | 0.781 ± 0.032 ^ b |
| MU             | 265.8 ± 15.6 ^ Ab | 353.1 ± 41.0 ^ A a | 494.1 ± 54.5 ^ b | 598.3 ± 93.9 ^ b |
| Time (Second)  | 115.8 ± 10.0 ^  | 206.3 ± 25.0 ^ A a | 160.9 ± 17.6 ^ B b | 189.1 ± 27.0 ^ B a |

^A" is statistically significantly different from "B" (p < 0.05); "a" is statistically significantly different from "b" (p < 0.05). No other statistically significant difference was found between any two (p > 0.05)
the 4-F IMRT plan (6 points) with 2 points from heart and CA. From the individual plan comparison (Table 6), we found that 2-F IMRT plan showed advantage on multiple indices for almost patients. And for heart and CA, the 2-F IMRT and 1-arc VMAT also showed equally most appearance score (both 3 point) (Table 6). These results suggested that there might be a clinical advantage for using 2-F IMRT over other plans in overall consideration.

Discussion
Planning comparisons and dosimetric studies of different field IMRT or VMAT in breast cancer have been evaluated in a large number of studies and there’s always been a debate on employing which technique in the radiation practice. This study compares different arcs of VMAT and fields of IMRT in radiotherapy planning, and evaluates the plans with the quality score table which focused on heart dose and coronary area in left sided breast cancer radiotherapy. However, the advantage of suitable radiotherapy plan for the patients with relative smaller breast has not been fully clarified.

Patients with early stage left breast cancer could survive for a long time and adapt to receive techniques that may reduce the incidence of acute and late toxicity induced by

| Table 3 Dose comparison of the ipsilateral lung, the contralateral lung, contralateral breast, liver, esophagus, and spinal cord in the four plans |
|---|---|---|---|---|
| Structure | Dose parameter | 2FIMRT | 4FIMRT | 2ArcVMAT | 1ArcVMAT |
| Body-PTV | D<sub>mean</sub>(Gy) | 2.2 ± 0.7<sup>A</sup> | 2.4 ± 0.7<sup>A</sup> | 2.3 ± 0.7<sup>A</sup> | 2.8 ± 0.8<sup>B</sup> |
| ID (Gy*litre) | 43.7 ± 13.5<sup>A</sup> | 48.0 ± 13.9<sup>Ba</sup> | 44.7 ± 13.6<sup>Ab</sup> | 54.5 ± 16.7<sup>Rb</sup> |
| Left Lung | D<sub>mean</sub>(Gy) | 4.9 ± 2.4<sup>A</sup> | 5.2 ± 2.1 | 5.0 ± 2.0<sup>A</sup> | 5.4 ± 1.8<sup>B</sup> |
| V5 | 16.6 ± 7.9%<sup>A</sup> | 19.1 ± 7.7%<sup>B</sup> | 18.4 ± 7.2%<sup>Ba</sup> | 21.7 ± 6.9%<sup>Bb</sup> |
| V20 | 9.3 ± 5.1% | 9.5 ± 4.7% | 9.2 ± 4.2% | 9.3 ± 4.1% |
| V40 | 4.3 ± 2.8%<sup>A</sup> | 3.7 ± 2.3%<sup>Ba</sup> | 3.8 ± 2.2%<sup>A</sup> | 3.1 ± 1.9%<sup>Bb</sup> |
| Right Lung | D<sub>mean</sub>(Gy) | 0.2 ± 0.1<sup>A</sup> | 0.3 ± 0.2<sup>A</sup> | 0.3 ± 0.1<sup>A</sup> | 0.8 ± 0.4<sup>B</sup> |
| V5 | 0.0 ± 0.0%<sup>A</sup> | 0.4 ± 1.0% | 0.0 ± 0.1%<sup>A</sup> | 0.9 ± 1.5%<sup>Bb</sup> |
| Right breast | D<sub>mean</sub>(Gy) | 0.5 ± 0.3<sup>A</sup> | 0.8 ± 0.4<sup>Ba</sup> | 0.9 ± 0.3<sup>Ba</sup> | 1.8 ± 0.8<sup>Bb</sup> |
| V5 | 0.1 ± 0.2%<sup>A</sup> | 1.9 ± 1.9%<sup>Ba</sup> | 0.6 ± 1.1%<sup>Ba</sup> | 1.5 ± 2.3%<sup>Bb</sup> |
| Esophagus | D<sub>mean</sub>(Gy) | 0.3 ± 0.1<sup>A</sup> | 0.4 ± 0.1<sup>A</sup> | 0.4 ± 0.1<sup>A</sup> | 0.7 ± 0.3<sup>B</sup> |
| Liver | D<sub>mean</sub>(Gy) | 0.2 ± 0.1<sup>A</sup> | 0.2 ± 0.1<sup>A</sup> | 0.3 ± 0.2<sup>A</sup> | 1.0 ± 0.7<sup>B</sup> |
| Spinal cord | D<sub>mean</sub>(Gy) | 0.1 ± 0.0<sup>A</sup> | 0.2 ± 0.0<sup>A</sup> | 0.2 ± 0.0<sup>A</sup> | 0.4 ± 0.2<sup>B</sup> |

<sup>A</sup> is statistically significantly different from <sup>B</sup> (<i>p</i> < 0.05); <sup>a</sup> is statistically significantly different from <sup>b</sup> (<i>p</i> < 0.05). No other statistically significant difference was found between any two (<i>p</i> > 0.05).

| Table 4 Dose comparison of the heart, coronary artery and heart minus coronary artery in the four plans |
|---|---|---|---|---|
| Structure | Dose parameter | 2FIMRT | 4FIMRT | 2ArcVMAT | 1ArcVMAT |
| Heart | D<sub>mean</sub>(Gy) | 2.8 ± 1.0<sup>A</sup> | 3.0 ± 1.4<sup>A</sup> | 3.3 ± 1.3<sup>B</sup> | 3.7 ± 1.4<sup>Rb</sup> |
| D<sub>max</sub>(Gy) | 50.2 ± 2.3<sup>A</sup> | 48.2 ± 3.7<sup>Ba</sup> | 44.1 ± 15.7 | 45.4 ± 5.2<sup>Rb</sup> |
| V5 | 8.6 ± 3.8%<sup>A</sup> | 11.0 ± 6.9%<sup>A</sup> | 13.7 ± 7.0%<sup>B</sup> | 16.6 ± 92%<sup>Rb</sup> |
| V20 | 3.4 ± 1.7%<sup>A</sup> | 3.3 ± 2.3%<sup>A</sup> | 3.7 ± 2.4%<sup>B</sup> | 3.4 ± 2.6%<sup>A</sup> |
| V40 | 0.9 ± 0.5%<sup>A</sup> | 0.7 ± 0.5%<sup>B</sup> | 0.9 ± 0.6%<sup>A</sup> | 0.4 ± 0.5%<sup>Bb</sup> |
| CA | D<sub>mean</sub>(Gy) | 13.2 ± 3.9 | 13.3 ± 4.0 | 12.7 ± 5.8 | 12.7 ± 4.3 |
| D<sub>max</sub>(Gy) | 50.2 ± 1.7<sup>A</sup> | 48.7 ± 3.7<sup>A</sup> | 48.9 ± 5.3<sup>A</sup> | 45.6 ± 4.9<sup>B</sup> |
| V5 | 56.4 ± 15.4%<sup>A</sup> | 60.8 ± 16.6% | 62.1 ± 18.6% | 62.7 ± 15.2%<sup>B</sup> |
| V20 | 26.1 ± 10.5% | 25.7 ± 10.9% | 27.2 ± 12.3%<sup>A</sup> | 24.8 ± 13.3%<sup>B</sup> |
| V40 | 7.3 ± 3.8%<sup>A</sup> | 5.9 ± 3.5%<sup>A</sup> | 6.8 ± 4.0%<sup>A</sup> | 3.3 ± 3.5%<sup>B</sup> |
| Heart-CA | D<sub>mean</sub>(Gy) | 1.4 ± 0.5<sup>A</sup> | 1.8 ± 0.9<sup>Ba</sup> | 2.0 ± 0.9<sup>Ba</sup> | 2.5 ± 1.0<sup>Rb</sup> |
| V5 | 2.4 ± 2.0%<sup>A</sup> | 5.6 ± 5.3%<sup>Da</sup> | 7.3 ± 6.1%<sup>B</sup> | 10.5 ± 8.5%<sup>Rb</sup> |
| V20 | 0.3 ± 0.6% | 0.6 ± 1.2% | 0.6 ± 1.2% | 0.6 ± 1.1% |
| V40 | 0.1 ± 0.2% | 0.1 ± 0.2% | 0.1 ± 0.2% | 0.0 ± 0.1% |

<sup>A</sup> is statistically significantly different from <sup>B</sup> (<i>p</i> < 0.05); <sup>a</sup> is statistically significantly different from <sup>b</sup> (<i>p</i> < 0.05). No other statistically significant difference was found between any two (<i>p</i> > 0.05).
radiotherapy. The cardiovascular complications induced by radiation— as a main radiotherapy-related late toxicity event progresses over time, and may manifest decades after the initial exposure [19]. The coronary artery injury was considered to be the most serious radiation-related complication in the heart. Darby SC et al. reported that exposure of the heart to ionizing radiation during radiotherapy for breast cancer increases the subsequent rate of ischemic heart disease linearly with the mean dose to the heart by 7.4 % per gray, with no apparent threshold [20]. Other studies further suggested that 1 Gy irradiation added to the mean heart dose could increase the cardiotoxic risk by 4 % [21]. Several studies had observed substantial radiation-induced heart disease linearly with the mean dose to the heart by 7.4 % per gray, with no apparent threshold [20]. Other studies further suggested that 1 Gy irradiation added to the mean heart dose could increase the cardiotoxic risk by 4 % [21]. Several studies had observed substantial radiation-induced heart disease linearly with the mean dose to the heart by 7.4 % per gray, with no apparent threshold [20]. Other studies further suggested that 1 Gy irradiation added to the mean heart dose could increase the cardiotoxic risk by 4 % [21]. Several studies had observed substantial radiation-induced heart disease linearly with the mean dose to the heart by 7.4 % per gray, with no apparent threshold [20]. Other studies further suggested that 1 Gy irradiation added to the mean heart dose could increase the cardiotoxic risk by 4 % [21]. Several studies had observed substantial radiation-induced heart disease linearly with the mean dose to the heart by 7.4 % per gray, with no apparent threshold [20]. Other studies further suggested that 1 Gy irradiation added to the mean heart dose could increase the cardiotoxic risk by 4 % [21]. Several studies had observed substantial radiation-induced heart disease linearly with the mean dose to the heart by 7.4 % per gray, with no apparent threshold [20]. Other studies further suggested that 1 Gy irradiation added to the mean heart dose could increase the cardiotoxic risk by 4 % [21]. Several studies had observed substantial radiation-induced heart disease linearly with the mean dose to the heart by 7.4 % per gray, with no apparent threshold [20]. Other studies further suggested that 1 Gy irradiation added to the mean heart dose could increase the cardiotoxic risk by 4 % [21]. Several studies had observed substantial radiation-induced heart disease linearly with the mean dose to the heart by 7.4 % per gray, with no apparent threshold [20]. Other studies further suggested that 1 Gy irradiation added to the mean heart dose could increase the cardiotoxic risk by 4 % [21]. Several studies had observed substantial radiation-induced heart disease linearly with the mean dose to the heart by 7.4 % per gray, with no apparent threshold [20]. Other studies further suggested that 1 Gy irradiation added to the mean heart dose could increase the cardiotoxic risk by 4 % [21]. Several studies had observed substantial radiation-induced heart disease linearly with the mean dose to the heart by 7.4 % per gray, with no apparent threshold [20]. Other studies further suggested that 1 Gy irradiation added to the mean heart dose could increase the cardiotoxic risk by 4 % [21]. Several studies had observed substantial radiation-induced heart disease linearly with the mean dose to the heart by 7.4 % per gray, with no apparent threshold [20]. Other studies further suggested that 1 Gy irradiation added to the mean heart dose could increase the cardiotoxic risk by 4 % [21]. Several studies had observed substantial radiation-induced heart disease linearly with the mean dose to the heart by 7.4 % per gray, with no apparent threshold [20]. Other studies further suggested that 1 Gy irradiation added to the mean heart dose could increase the cardiotoxic risk by 4 % [21]. Several studies had observed substantial radiation-induced heart disease linearly with the mean dose to the heart by 7.4 % per gray, with no apparent threshold [20]. Other studies further suggested that 1 Gy irradiation added to the mean heart dose could increase the cardiotoxic risk by 4 % [21]. Several studies had observed substantial radiation-induced heart disease linearly with the mean dose to the heart by 7.4 % per gray, with no apparent threshold [20]. Other studies further suggested that 1 Gy irradiation added to the mean heart dose could increase the cardiotoxic risk by 4 % [21]. Several studies had observed substantial radiation-induced heart disease linearly with the mean dose to the heart by 7.4 % per gray, with no apparent threshold [20]. Other studies further suggested that 1 Gy irradiation added to the mean heart dose could increase the cardiotoxic risk by 4 % [21]. Several studies had observed substantial radiation-induced heart disease linearly with the mean dose to the heart by 7.4 % per gray, with no apparent threshold [20]. Other studies further suggested that 1 Gy irradiation added to the mean heart dose could increase the cardiotoxic risk by 4 % [21]. Several studies had observed substantial radiation-induced heart disease linearly with the mean dose to the heart by 7.4 % per gray, with no apparent threshold [20]. Other studies further suggested that 1 Gy irradiation added to the mean heart dose could increase the cardiotoxic risk by 4 % [21]. Several studies had observed substantial radiation-induced heart disease linearly with the mean dose to the heart by 7.4 % per gray, with no apparent threshold [20]. Other studies further suggested that 1 Gy irradiation added to the mean heart dose could increase the cardiotoxic risk by 4 % [21]. Several studies had observed substantial radiation-induced heart disease linearly with the mean dose to the heart by 7.4 % per gray, with no apparent threshold [20]. Other studies further suggested that 1 Gy irradiation added to the mean heart dose could increase the cardiotoxic risk by 4 % [21].

Table 5 Plan score table of the four treatment techniques

| Structure   | Dose Parameter | 2 F-IMRT | 4 F-IMRT | 2Arc-VMAT | 1Arc-VMAT |
|-------------|----------------|----------|----------|-----------|-----------|
| PTV         | HI             | 0        | 0        | 1         | 1         |
|             | CI             | 0        | 0        | 1         | 1         |
|             | CN             | 0        | 0        | 1         | 1         |
|             | MU             | 1        | 0        | 0         | 0         |
|             | Time           | 1        | 0        | 0         | 0         |
| LungL       | D_{\text{mean}} | 1        | 0        | 1         | 0         |
|             | V5             | 1        | 0        | 1         | 0         |
|             | V20            | 0        | 0        | 0         | 0         |
|             | V40            | 0        | 0        | 0         | 1         |
| Heart       | D_{\text{mean}} | 1        | 1        | 0         | 0         |
|             | V5             | 1        | 0        | 0         | 0         |
|             | V20            | 1        | 1        | 0         | 1         |
|             | V40            | 0        | 0        | 0         | 1         |
| Coronary artery | D_{\text{mean}} | 0       | 0        | 0         | 0         |
|             | V5             | 1        | 0        | 0         | 0         |
|             | V20            | 0        | 0        | 0         | 1         |
|             | V40            | 0        | 0        | 0         | 1         |
| Healthy tissue | D_{\text{mean}} | 1       | 1        | 1         | 0         |
| Breast.R    | D_{\text{mean}} | 1       | 0        | 0         | 0         |
| Liver       | D_{\text{mean}} | 1       | 1        | 1         | 0         |
| P-cord      | D_{\text{mean}} | 1       | 1        | 1         | 0         |
| Eso         | D_{\text{mean}} | 1       | 1        | 1         | 0         |
| Lung.R      | D_{\text{mean}} | 1       | 0        | 1         | 0         |
| Total Score |                | 14       | 6        | 10        | 8         |
| Scores from Heart and CA |                  | 4        | 2        | 0         | 4         |

Results on D_{\text{mean}}, V5 and V20 for heart and V5 for coronary arteries. This meant the 2-F IMRT and 1-arc VMAT plan showed a statistically significant improvement for heart dose for left-sided breast irradiation.

Nowadays, the developed radiation techniques could also be used to spare the cardiac area sparing in breast radiation practice. It was reported that radiation delivering in Deep Inspiration Breath Hold (DIBH) conditions could reduce the dose to heart for left-sided breast cancer patients [24]. Some other studies demonstrated that whole breast irradiation with prone position seems to be beneficial for 85 % of the patients regarding heart irradiation [25]. Further studies found that IMRT with prone position is superior to supine treatment for right-sided breast cancer patients and left-sided breast cancer patients with larger breasts [26] and benefited most from prone position with DIBH for heart sparing by radiation dose [27]. But for patients of smaller breast volume in left side, some studies argued that the prone position might result in worse cardiac dosimetry than supine position [28, 29].
Moreover, when a dose comparison of heart minus coronary artery calculated, the observed V20 and V40 for the rest of heart, in all plans were very small and closed, suggesting that the dose volume for the coronary arteries can be used to predict the dose volume of the high dose for the entire heart.

For other OARs, it has been reported that the doses to the ipsilateral lung have been shown to be responsible for radiation pneumonia in breast cancer radiotherapy [30]. Dosimetric parameters of mean lung dose and V20 showed a significant correlation with the development of radiation-induced pneumonitis in radiotherapy for breast cancer [31, 32]. In our study, we found that for D_{mean} and V5 to ipsilateral lung, the best results were from 2-F IMRT and 2-arc VMAT plans, and the V20 to the ipsilateral lung was uneventful in all plans. In addition, the 2-F IMRT, 4-F IMRT and 2-arc VMAT plans were associated with the most favorable dose deposition in the liver, esophagus, spinal cord, contralateral lung compared with 1-arc VMAT.

Except for acute and late radiation damage induced by high dose radiation, the low dose irradiation raises the concern of radiation-induced secondary malignancy [33]. The delivery of low-dose irradiation to healthy tissue, especially to the contralateral breast, has been estimated to double the risk of subsequent malignancy [34], and this risk increases with increasing dose [15]. Based on our study, it was demonstrated that 2-F IMRT and 2-arc VMAT resulted in a reduction of the mean dose to healthy tissue and ID as compared with that in other plans. And the 2-F IMRT plan also showed advantage on D_{mean} in contralateral breast. So from the overall consideration we suggest to choose 2-F IMRT with the highest scores which was suitable for the protection of heart and coronary artery in left-sided breast cancer radiotherapy. We also found that 2-arc VMAT technique with the second highest scores could improve the homogeneity and conformity in PTV and sparing of some OARs in some dosimetric indications. So if the doctor has not concerns on the heart and coronary artery, the 2-arc VMAT technique may also be a good choice. The 1-arc VMAT plan with fewer composite scores has apparent advantages on D_{max} and high doses regions to heart and coronary artery, which might also be a selective plan for sparing heart dose in practice. The 4-F

| Table 6 Individual plan comparison table |
|------------------------------------------|
| Structure | Parameter | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | Most Appearance |
| PTV | HI | 2A | 2A | 4F | 2A | 2A | 1A | 1A | 1A | 1A | 2A | 2A | 2A |
| Cl | 1A | 1A | 1A | 1A | 1A | 1A | 1A | 1A | 1A | 1A | 1A | 1A | 1A |
| CN | 1A | 1A | 1A | 1A | 1A | 1A | 1A | 1A | 1A | 1A | 1A | 1A | 1A |
| MU | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2F |
| Time | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2F |
| Lung.L | D_{mean} | 2F | 2F | 2F | 2F | 2F | 2A | 2A | 2F | 2F | 2F | 2F | 2F |
| V5 | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2A | 2A | 2F | 1A | 4F |
| V20 | 2F | 2F | 2A | 2F | 2F | 1A | 1A | 1A | 1A | 1A | 4F | 2F | 1A |
| V40 | 4F | 1A | 1A | 1A | 4F | 1A | 1A | 1A | 1A | 4F | 1A | 1A |
| Heart | V5 | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 1A | 1A | 1A | 1A | 1A |
| V40 | 4F | 1A | 1A | 1A | 4F | 1A | 1A | 1A | 1A | 1A | 1A | 1A |
| CA | D_{mean} | 4F | 4F | 1A | 2F | 4F | 1A | 1A | 2A | 4F | 1A | 1A |
| V5 | 2F | 2F | 4F | 2F | 2F | 4F | 2F | 4F | 2A | 4F | 1A | 1A |
| V20 | 4F | 4F | 4F | 2F | 4F | 4F | 4F | 1A | 2A | 4F | 1A | 1A |
| V40 | 4F | 1A | 1A | 4F | 1A | 1A | 1A | 1A | 4F | 1A | 1A |
| Healthy tissue | D_{mean} | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2F |
| Breast.R | D_{mean} | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2F |
| Liver | D_{mean} | 2A | 2A | 2F | 2F | 2F | 4F | 2F | 2A | 4F | 2F | 2F |
| P-cord | D_{mean} | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2F |
| Eso | D_{mean} | 2F | 2F | 2F | 2A | 2F | 2F | 2F | 2A | 2F | 2F | 2F |
| Lung.R | D_{mean} | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2F |
| Most Appearance | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 2F | 1A | 2F | 2A | 1A | 2F |

Abbreviations: 1A 1-arc VMAT, 2A 2-arc VMAT, 2 F 2-F IMRT, 4 F 4-F IMRT
IMRT plans did not show special advantages when compared with other plans in our research.

Conclusion
In conclusion, compared with other plans, the 2-F IMRT plan has demonstrated the combined advantages in PTV dose coverage and dose drop to most normal tissue involved in our research, besides for the heart and coronary artery. So we suggest employing 2-F IMRT plan for left breast cancer radiotherapy after breast-conserving surgery.

Consent
Written information consent was obtained from the patient for publication of this report and any accompanying images.

Abbreviations
CA: coronary artery; CTV: clinical target volume; IMRT: intensity-modulated radiation therapy; OARs: organs at risk; PTV: planning target volume; VMAT: volumetric-modulated arc therapy.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
GH Cheng designed the study and gave advice on the manuscript revision. HF Zhao participated in data collection, data analysis and table/figure creation. MY He drafted the manuscript and revised the manuscript. N Wu helped for English checking and correcting. ZP Zhao and D Shi involved in delineating the GTV, CTV and OARs. DM Han participated in the statistical analysis of the data. JX Jin gave some helpful advice about the study and the revision. All authors read and approved the final manuscript.

Funding
This work was supported by the Bethune Medical Scientific Research Support Plan of Jilin University - frontier interdisciplinary innovation project (2013107024), the fund of the Department of Science and Technology of Jilin Province (20090458), the fund of the Health and Family Planning Commission Project of Jilin Province (2014ZC054).

Author details
1Department of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun 130033, China. 2Department of Radiation Physics, Elekta China Co. Ltd, Beijing 100101, China.

Received: 2 February 2015 Accepted: 28 October 2015 Published online: 17 November 2015

References
1. Sardaro A, Petruzelli MF, D’Errico MF, Grimaldi L, Pili G, Portaliu M. Radiation-induced cardiac damage in early left breast cancer patients: risk factors, biological mechanisms, radiobiology, and dosimetric constraints. Radiother Oncol. 2012;103(2):133–42.
2. McLaughlin SA, Ochoa-Frongia LM, Patil SM, Cody 3rd HS, Sclafani LM. Influence of frozen-section analysis of sentinel lymph node and lumpectomy margin status on reoperation rates in patients undergoing breast-conservation therapy. J Am Coll Surg. 2008;206(1):76–82.
3. Darby S, McGale P, Correa C, Taylor C, Ariaguda R, Clarke M, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 108,001 women in 17 randomized trials. Lancet. 2013;380(9840):1707–16.
4. Hooping MJ, Botma A, Alleen BM, Baaijens MH, Bartelink H, Klein JS, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. 2007;99(5):365–75.
5. Henson KE, McGale P, Taylor C, Darby SC. Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer. Br J Cancer. 2013;108(1):179–82.
6. Morgan EA, Kozono DE, Wang Q, Mery CM, Butrynski JE, Baldini EH, et al. Cutaneous radiation-associated angiosarcoma of the breast: poor prognosis in a rare secondary malignancy. Ann Surg Oncol. 2012;19(12):3880–8.
7. Paszat LF, Mackillop WJ, Groome PA, Schulze K, Holowaty E. Mortality from myocardial infarction following post lumpectomy radiotherapy for breast cancer: a population-based study in Ontario, Canada. Int J Radiat Oncol Biol Phys. 1999;43(4):75–62.
8. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–106.
9. Donovan E, Bleakley N, Denholm E, Evans P, Gothard L, Hanson J, et al. Randomised trial of standard 2D radiotherapy (RT) versus intensity-modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol. 2007;82(3):254–64.
10. Keller LM, Sopka DM, Li T, Clayton T, Li J, Anderson PR, et al. Five-year results of whole breast intensity modulated radiation therapy for the treatment of early stage breast cancer: the Fox Chase Cancer Center experience. Int J Radiat Oncol Biol Phys. 2012;84(4):988–7.
11. Popescu CC, Olivetto IA, Beckham WA, Anscher M, Zavgorodni S, Shaffer R, et al. Volumetric modulated arc therapy improves dosimetry and reduces treatment time compared to conventional intensity-modulated radiotherapy for locoregional radiotherapy of left-sided breast cancer and internal mammary nodes. Int J Radiat Oncol Biol Phys. 2010;77(1):287–95.
12. Dogan N, Cuturco L, Lloyd R, Bump EA, Arthur DW. Optimized dose coverage of regional lymph nodes in breast cancer: the role of intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2007;68(4):1238–50.
13. Pasler M, Georg D, Bartelt S, Lutterbach J. Node-positive left-sided breast cancer: does VMAT improve treatment plan quality with respect to IMRT? Strahlenther Onkol. 2013;189(5):380–6.
14. Badakhshi H, Kaul D, Nabobry J, Wille B, Sehoului J, Budach V. Image-guided volumetric modulated arc therapy for breast cancer: a feasibility study and plan comparison with three-dimensional conformal and intensity-modulated radiotherapy. Br J Radiol. 2013;86(1032):20130515.
15. Hong L, Hunt M, Chui C, Spiro S, Forster K, Lee H, et al. Intensity-modulated tangential beam irradiation of the intact breast. Int J Radiat Oncol Biol Phys. 1999;44(3):1155–64.
16. International Commission on Radiation Units and Measurements (ICRU). Prescribing, Recording, and Reporting Photon-Beam Intensity-Modulated Radiation Therapy (IMRT). ICRU report 78. 2010. doi: 10.1093/icru/icp002.
17. Hodapp N. The ICRU Report 83: prescribing, recording and reporting photon-beam intensity-modulated radiation therapy (IMRT). Strahlenther Onkol. 2012;188(1):97–9.
18. Paddick I. A simple scoring ratio to index the conformity of radiosurgical treatment plans. Technical note. J Neurosurg. 2000;93 Suppl 3:219–22.
19. Moussavi N, Nohria A. Radiation-induced cardiovascular disease. Curr Treat Options Cardiovasc Med. 2013;15(5):507–17.
20. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Bronnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(1):987–98.
21. Mege A, Zioleque A, Porel N, Chauvet B. Radiation-related heart toxicity. Cancer Radiother. 2011;15(6–7):495–503.
22. Cosset JM, Henry-Amar M, Pellae-Cosset B, Carde P, Girinski T, Tubiana M, et al. Pericarditis and myocardial infarctions after Hodgkin’s disease therapy. Int J Radiat Oncol Biol Phys. 1991;21(2):447–9.
23. Ishikura S, Nihei K, Ohtsu A, Boku N, Hironaka S, Mera K, et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol. 2003;21(14):2697–702.
24. Buzzoni V, Abate A, Pinnaro P, D’Andrea M, Infusino E, Landoni V, et al. Dosimetric and clinical advantages of deep inspiration breath-hold (DIBH) during radiotherapy of breast cancer. J Exp Clin Cancer Res. 2013;32:88.
25. Formenti SC, Gideau-Addeo D, Goldberg JD, Roses DF, Guth A, Rosenberg BS, et al. Phase II trial of prone accelerated intensity modulated radiation therapy to the breast to optimally spare normal tissue. J Clin Oncol. 2007;25(16):2236–42.
26. Muletz T, Speeles B, Madani I, De Gendem W, Veldeman L, De Neve W. Whole breast radiotherapy in prone and supine position: is there a place for multi-beam IMRT? Radiat Oncol. 2013;8:151.
27. Muletz T, Veldeman L, Speeles B, Mahjoubi K, Remouchamps V, Van Gervel A, et al. Heart dose reduction by prone deep inspiration breath hold in left-sided breast irradiation. Radiother Oncol. 2015;114(1):79–84.
28. Lymberis SC, DeWyngaert JK, Parhar P, Chhabra AM, Fenton-Kerimian M, Chang J, et al. Prospective assessment of optimal individual position (prone versus supine) for breast radiotherapy: volumetric and dosimetric correlations in 100 patients. Int J Radiat Oncol Biol Phys. 2012;84(4):902–9.

29. Formenti SC, DeWyngaert JK, Jozsef G, Goldberg JD. Prone vs supine positioning for breast cancer radiotherapy. JAMA. 2012;308(9):861–3.

30. Tajvidi M, Sirous M, Sirous R, Hajian P. Partial frequency of radiation pneumonitis and its association with the energy and treatment technique in patients with breast cancer, Isfahan, Iran. J Res Med Sci. 2013;18(5):413–6.

31. Chung Y, Yoon HJ, Kim YB, Ahn SK, Keum KC, Suh CO. Radiation pneumonitis in breast cancer patients who received radiotherapy using the partially wide tangent technique after breast conserving surgery. J Breast Cancer. 2012;15(3):337–43.

32. Lind PA, Wennberg B, Gagliardi G, Rosfors S, Blom-Goldman U, Lidestahl A, et al. ROC curves and evaluation of radiation-induced pulmonary toxicity in breast cancer. Int J Radiat Oncol Biol Phys. 2006;64(3):765–70.

33. Dorr W, Herrmann T. Second primary tumors after radiotherapy for malignancies. Treatment-related parameters. Strahlenther Onkol. 2002;178(7):357–62.

34. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys. 2006;65(1):1–7.